|
by Deonandan, Raywat, Jones, Sarah
Published 2017
“... the intravitreal use of bevacizumab, citing increased risk of ophthalmic complications. In addition...”Published 2017
Canadian Agency for Drugs and Technologies in Health
|
by Deonandan, Raywat, Jones, Sarah
Published 2017
“... the intravitreal use of bevacizumab, citing increased risk of ophthalmic complications. In addition...”Published 2017
Canadian Agency for Drugs and Technologies in Health